FVIII and FIX inhibitors in people living with hemophilia in <scp>C</scp>ameroon, <scp>A</scp>frica: a preliminary study

Tagny, Claude Tayou; Ndoumba, Annick; Mbanya, Dora

doi:10.1111/ijlh.12190

Cited by 5 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data on inhibitors and molecular diagnosis in PWH are scarce in Sub-Saharan Africa. 15,16 This is the first prospective study in 17,18 We reported a similar distribution of intron 22 inversions, point variants and rearrangements compared to non-African ethnic groups. This distribution had previously been reported in studies from Senegal and South Africa.…”

Section: Discussionmentioning

confidence: 61%

“…Finally, we compared our results on prevalence of inhibitor and genetic‐related risk factors for inhibitor development (if available with those obtained from other Sub‐Saharan African countries (Cameroon, Senegal and South Africa) and reported in peer‐reviewed journals.…”

Section: Methodsmentioning

confidence: 99%

“…[15][16][17][18] In 2015, a World Federation of Hemophilia (WFH) twinning programme was established between the Yopougon Hemophilia Treatment Center (HTC) in Abidjan, Côte d'Ivoire, and the international HTC of the Cliniques universitaires Saint-Luc in Brussels, Belgium. [15][16][17][18] In 2015, a World Federation of Hemophilia (WFH) twinning programme was established between the Yopougon Hemophilia Treatment Center (HTC) in Abidjan, Côte d'Ivoire, and the international HTC of the Cliniques universitaires Saint-Luc in Brussels, Belgium.…”

mentioning

confidence: 99%

“…In Sub-Saharan African countries, data on inhibitor prevalence and causal haemophilia variants are scarce. [15][16][17][18] In 2015, a World Federation of Hemophilia (WFH) twinning programme was established between the Yopougon Hemophilia Treatment Center (HTC) in Abidjan, Côte d'Ivoire, and the international HTC of the Cliniques universitaires Saint-Luc in Brussels, Belgium. In this setting, we studied genotypes, inhibitor prevalence, genetic-related risk factors and exposition to CFCs among Ivoirian PWHs.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Inhibitor epidemiology and genetic‐related risk factors in people with haemophilia from Côte d’Ivoire

et al. 2019

View full text Add to dashboard Cite

Introduction In Sub‐Saharan Africa, inhibitor prevalence data in people with haemophilia (PWH) are scarce, as are data on genetic or treatment‐related risk factors. Aims and methods We performed a prospective study on PWH from Côte d’Ivoire to collect data into inhibitor prevalence, create a database of haemophilia genotypes, establish correlations between inhibitor presence and genetic variants identified amongst Ivoirian PWHs and evaluate exposure to CFCs. Results The study included 54 unrelated participants (43 severe, four moderate, two mild haemophilia A and five severe haemophilia B). PWH were treated on‐demand with various product types for short periods, non‐intensively, and using low‐dose regimens. We reported similar distributions of intron 22 inversions (39.5%), point pathogenic variants (32.6%) and rearrangements in Ivoirian severe haemophilia A patients versus non‐African ethnic groups. The haplotypes H1 (29.6%), H2 (36.3%) and H3 (34.1%) frequencies in haemophilia A were consistent with results published on African populations. We identified eight new causal variants. An inhibitor was found in 12% of haemophilia A patients previously exposed to replacement therapies. Among PWH with inhibitors, 66.7% had a positive intron 22 inversion and 50% the H1 haplotype. Conclusion This study provides original data on molecular diagnosis of haemophilia, inhibitor prevalence and risk factors for inhibitor development previously associated with inhibitors in Côte d’Ivoire. The low inhibitor prevalence likely reflects the limited exposure to replacement therapy in Côte d’Ivoire. Further larger, multicentric and international studies are needed to gain more insight on inhibitor incidence and risk factors in African PWH.

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Inhibitor epidemiology and genetic‐related risk factors in people with haemophilia from Côte d’Ivoire

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Hence, there is paucity of data on haemophilia and its management in Cameroon. To date, few available data report just over 100 diagnosed and registered cases [5]. The role of the WFH is to work together with national associations to promote the well-being of PLWH worldwide.…”

Section: Introductionmentioning

confidence: 99%

Assessing the quality of care for haemophilia at the Yaoundé reference treatment Centre of Cameroon

Ct²,

Am³

et al. 2017

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

With a recently established Haemophilia Treatment Centre (HTC) in Yaoundé, Cameroon, over a hundred people living with haemophilia have been recruited and followed up at this centre. This study aimed at assessing the quality of haemophilia care provided at the HTC, in order to monitor and improve patient care. In February 2014, the HTC was assessed using recommended markers. Although few, the logistics and reagents for the diagnosis and treatment of haemophilia were available. There were seven trained workers involved with haemophilia care, but the multidisciplinary care team was incomplete. A total of 113 people living with haemophilia (all males) had been registered and regularly followed up at the HTC. This study showed that the HTC of the Yaoundé University Teaching Hospital, although not yet ideal, allows for some degree of haemophilia patient care. Hence, it may be recommended to improve the centre and make it fully established in Cameroon.

show abstract

Hemophilia care in Africa: Status and challenges

Mbanya

Diop

Mintya

et al. 2021

Transfusion Clinique et Biologique

View full text Add to dashboard Cite

FVIII and FIX inhibitors in people living with hemophilia in Cameroon, Africa: a preliminary study

Abstract: The frequency of inhibitors in hemophiliac patient undergoing replacement therapy is high in Cameroon. Severity of disease was found to be the main contributing factor in patients who developed inhibitors.

Cited by 5 publications

References 7 publications

Inhibitor epidemiology and genetic‐related risk factors in people with haemophilia from Côte d’Ivoire

Inhibitor epidemiology and genetic‐related risk factors in people with haemophilia from Côte d’Ivoire

Assessing the quality of care for haemophilia at the Yaoundé reference treatment Centre of Cameroon

Hemophilia care in Africa: Status and challenges

Contact Info

Product

Resources

About